Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Evaluating the prognostic value of time to metastasis in metachronous mHSPC

Nicolas Sayegh • 15 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer
SWOG S1216

Nicolas Sayegh, MD, University of Utah, Salt Lake City, UT, discusses the impact of time to metastatic recurrence after prostatectomy on survival outcomes in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC). Using data from the SWOG S1216 trial (NCT01809691), the analysis found no significant association between time to metastasis and progression-free or overall survival. These findings suggest that timing of metastatic recurrence should not be used as a prognostic marker or to guide treatment decisions in this patient population. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicolas Sayegh

Survival outcomes and characterization of mCSPC
2:24
Survival outcomes and characterization of mCSPC
Nicolas Sayegh • 17 Feb 2022
TMB as a predictive biomarker for ICI versus taxane chemotherapy benefit in mCRPC
3:06
TMB as a predictive biomarker for ICI versus taxane chemotherapy benefit in mCRPC
Nicolas Sayegh et al. • 18 Feb 2022
Genomic characterization of patients with de-novo high-volume mCSPC compared to those without
1:36
Genomic characterization of patients with de-novo high-volume mCSPC compared to those without
Nicolas Sayegh • 18 Feb 2022
OS after progression on first novel hormonal therapy in mCSPC vs mCRPC
1:46
OS after progression on first novel hormonal therapy in mCSPC vs mCRPC
Nicolas Sayegh • 18 Feb 2022

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals